News headlines about Otonomy (NASDAQ:OTIC) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.3885821211944 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s analysis:

Shares of Otonomy (NASDAQ OTIC) opened at $5.20 on Tuesday. Otonomy has a 1-year low of $2.80 and a 1-year high of $21.15.

Otonomy (NASDAQ:OTIC) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.15. The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.43 million. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. The firm’s revenue was down 12.8% compared to the same quarter last year. equities research analysts forecast that Otonomy will post -3 EPS for the current year.

A number of research firms recently weighed in on OTIC. Piper Jaffray Companies reissued a “hold” rating and set a $8.00 target price on shares of Otonomy in a research report on Friday. ValuEngine downgraded Otonomy from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cowen and Company reissued an “outperform” rating and set a $9.00 target price (down from $55.00) on shares of Otonomy in a research report on Thursday, August 31st. SunTrust Banks, Inc. reissued a “buy” rating and set a $15.00 target price (down from $45.00) on shares of Otonomy in a research report on Thursday, August 31st. Finally, J P Morgan Chase & Co downgraded Otonomy from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $28.00 to $8.00 in a research report on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Otonomy presently has a consensus rating of “Hold” and a consensus price target of $10.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at

Otonomy Company Profile

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Insider Buying and Selling by Quarter for Otonomy (NASDAQ:OTIC)

Receive News & Stock Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related stocks with our FREE daily email newsletter.